ReviewNature reviews. Rheumatology2018
B cells in the pathogenesis of primary Sjögren syndrome.
Review in Nature reviews. Rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 210 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
210 citing papers in PubMed, 4 syntheses or guidelines pooled it, 342 citations in OpenAlex.
- Global research landscape and emerging trends of tertiary lymphoid structures in autoimmune diseases: a bibliometric analysis.Frontiers in immunology · 2026Pooled it
- Meta-analysis of the efficacy and safety of rituximab in the treatment of primary Sjögren's syndrome.Frontiers in immunology · 2025Pooled it
- Elevated CXCL13 in primary Sjögren's syndrome and its correlation with disease activity: a systematic review and meta-analysis.Clinical rheumatology · 2022Pooled it
- Association Between Minor Salivary Gland Biopsy During Sjӧgren's Syndrome and Serologic Biomarkers: A Systematic Review and Meta-Analysis.Frontiers in immunology · 2021Pooled it
- A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary Sjögren's syndrome.Rheumatology (Oxford, England) · 2023Trial
- Article
- Phloretin Modulates STING Ubiquitination Degradation to Restrain Dendritic Cell Overactivation and Alleviate Sjögren's Syndrome.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Integrated machine learning framework identifies EPSTI1 as a key diagnostic biomarker for Sjögren's disease: multi-cohort transcriptomic validation and single-cell characterization.Clinical rheumatology · 2026Article
- [Pathophysiological aspects of primary Sjögren's disease : From epithelial activation to systemic autoimmunity].Zeitschrift fur Rheumatologie · 2026Review
- Low albumin-to-globulin ratio is associated with interstitial lung disease in primary Sjögren's syndrome: a single-center retrospective cohort study with propensity score matching.Rheumatology international · 2026Article
- Low-Density Granulocytes Link to Disease Activity, Organ Involvement, and Cytokine Production in Sjögren's Disease.International journal of molecular sciences · 2026Article
- Cytokine Networks and Clinical Heterogeneity in Sjögren's Disease: From Glandular Inflammation to Therapeutic Stratification.International journal of molecular sciences · 2026Review
- Sjögren Disease-B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell-Targeted Therapies.Arthritis & rheumatology (Hoboken, N.J.) · 2026Review
- Systems serology identifies FcR-related autoantibody signatures and functions for Sjögren's syndrome.EMBO molecular medicine · 2026Article
- Review
- From Molecular Pathophysiology to Clinical Trial Design in Sjögren's Disease: A Three-Axis Framework.International journal of molecular sciences · 2026Review
- Identification of a shared antigen linking CD4Science advances · 2026Article
- Salivary gland ultrasonographic abnormalities in systemic lupus erythematosus versus rheumatoid arthritis: a comparative cross-sectional study using OMERACT scoring.Journal of ultrasound · 2026Article
- B Cells and B Cell Depletion in Autoimmunity and Atherosclerosis.Life (Basel, Switzerland) · 2026Review
- Molecular Insights into Oral Manifestations in Sjögren's Disease.International journal of molecular sciences · 2026Review
150 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary Sjögren syndrome (pSS) is a prototypical autoimmune disease. The involvement of B cells in the pathogenesis of pSS has long been suspected on the basis of clinical observations that include the presence of serum autoantibodies, hypergammaglobulinaemia, increased levels of free light chains and increased risk of B cell lymphoma. Moreover, the composition of the B cell subset is altered in pSS. In this Review, we discuss the mechanisms that support the increased activation of B cells in pSS, including genetic and epigenetic factors and environmental triggers that promote B cell activation via the innate immune system. B cell activating factor (BAFF, also known as TNF ligand superfamily member 13B) is at the crossroads of this process. An important role also exists for the target tissue (exocrine glands, namely the salivary and lachrymal glands), which promotes local B cell activation. This continuous stimulation of B cells is the main driver of lymphomatous escape. Identification of the multiple steps that support B cell activation has led to the development of promising targeted therapies that will hopefully lead to the development of an efficient therapeutic strategy for pSS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.